Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

MLA

Murthy, Rashmi K., et al. “Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients with HER2-Positive Metastatic Breast Cancer.” Cancer, vol. 120, no. 13, July 2014, pp. 1932–38. EBSCOhost, https://doi.org/10.1002/cncr.28689.

APA

Murthy, R. K., Varma, A., Mishra, P., Hess, K. R., Young, E., Murray, J. L., Koenig, K. H., Moulder, S. L., Melhem-Bertrandt, A., Giordano, S. H., Booser, D., Valero, V., Hortobagyi, G. N., & Esteva, F. J. (2014). Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer, 120(13), 1932–1938. https://doi.org/10.1002/cncr.28689

Chicago

Murthy, Rashmi K, Ankur Varma, Priyankana Mishra, Kenneth R Hess, Elliana Young, James L Murray, Kimberly H Koenig, et al. 2014. “Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients with HER2-Positive Metastatic Breast Cancer.” Cancer 120 (13): 1932–38. doi:10.1002/cncr.28689.